[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616307":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":23,"centralContacts":24,"locations":30,"responsibleParty":49,"collaborators":23,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":23,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":23,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":23,"overallStatus":33,"whyStopped":23,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Definium Therapeutics US, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"200 mg DT402","EXPERIMENTAL","A psychoactive substance that mediates effects mainly through a release of the monoaminergic neurotransmitters, with the greatest effect on 5-HT, followed by NE and DA",[13],"Drug: DT402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"DRUG","DT402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))",[9],[20,21,22],"MM402","R-MDMA","MDMA",null,[25],{"name":26,"role":27,"phone":28,"phoneExt":23,"email":29},"Definium Therapeutics Clinical Trials Information Requests","CONTACT","1-332-282-0479","clinicaltrials@definiumtx.com",[31],{"facility":32,"status":33,"city":34,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Spectrum Neuroscience and Treatment Institute","RECRUITING","New York","10021","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-74.00597,40.71427,{"lat":42,"lon":41},[45],{"name":46,"role":27,"phone":47,"phoneExt":23,"email":48},"Casara Ferretti","1-914-315-4236","cferretti@spectrumneuroscience.org",{"type":50,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100616307","phase-2-a-phase-2a-trial-of-dt402-for-autism-spectrum-disorder-100616307",false,"NCT07303907","A Phase 2A Trial of DT402 for Autism Spectrum Disorder","An Open-label Study Evaluating DT402 in Adults With Autism Spectrum Disorder","Inclusion Criteria:\n\n1. Diagnosis of ASD per records as confirmed by standard semi-structured interview for Autism diagnosis (eg, Autism Diagnostic Observation Schedule-Second Edition)\n2. Male or Female aged 18 to 65\n3. Presents with clinically significant deficits in socialization and communication as determined by Social Responsiveness Scales (SRS-2) ≥66\n\nExclusion Criteria:\n\n1. Has uncorrected abnormalities in eye movement, alignment, or acuity or atypical eye features that could interfere with eye tracking\n2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder\n3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine)\n4. Any clinically significant unstable illness","ALL","18 Years","65 Years",{"count":62,"type":63},20,"ESTIMATED","INTERVENTIONAL",[66],"PHASE2","A Phase 2A Trial of DT402 Open-Label Study in Adults with Autism Spectrum Disorder",[69,70],"Autism Spectrum Disorder","ASD","2026-03-31",{"date":73,"type":74},"2026-04-06","ACTUAL",{"date":76,"type":74},"2025-12-03",{"date":78,"type":63},"2027-08",{"name":5,"class":6},1]